Rebound and withdrawal with benzodiazepine and non-benzodiazepine hypnotic medication

Clinical pharmacology of sleep

Volumn 9783764374402, Issue , 2006, Pages 225-234

  Lader, Malcolm ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919964721     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-7643-7440-3_15     Document Type: Chapter

References (55)

1. Ohayon MM, Lader MH (2002) Useof psychotropic medication inthe general population of France, Germany, Italy and the United Kingdom. J Clin Psychiat 63:817-825
2. Vermeeren A (2004) Residual effects of hypnotics. Epidemiology and clinical implications. CNS Drugs 18:297-328
3. Hesse LM, von Moltke LL, Greenblatt DJ (2003) Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 17:513-532
4. Lader M (1998) Withdrawal reactions after stopping hypnotics in patients with insomnia. CNS Drugs 10:425-440
5. Hajak G, Müller WE, Wittchen HU, Pitrow D, Kirch W (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371-1378
6. Roehrs T, Vogel G, Roth R (1990) Rebound insomnia: its determinants and significance. Am J Med 88, Suppl 3A:395-425
7. Soldatos CR, Dikeos DG, Whitehead A (1999) Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 14:287-303
8. Lader M, Lawson C (1987) Sleep studies and rebound insomnia: methodological problems, laboratory findings, and clinical implications. Clin Neuropharmacol 10:291-312
9. Lader M (1992) Rebound insomnia and newer hypnotics. Psychopharmacology 108:248-255
10. Gillin JC, Spinweber CL, Johnson LC (1989) Rebound insomnia: a critical review. J Clin Psychopharmacol 9:161-172
11. Kales A, Scharf MB, Bixler EO, Schweitzer PK, Jacoby JA, Soldatos CR (1981) Doseresponse studies of quazepam. Clin Pharmacol Ther 30:194-200
12. Adam K, Adamson L, Brezinova V, Hunter WM (1976) Nitrazepam: lastingly effective but trouble on withdrawal. BMJ 1:1558-1560
13. Oswald I, French C, Adam K, Gilham J (1982) Benzodiazepine hypnotics remain effective for 24 weeks. BMJ 284:860-863
14. Scharf MB, Bixler EO, Kales A, Soldatos CR (1979) Long-term sleep laboratory evaluation of flunitrazepam. Pharmacology 19:173-181
15. Mamelak M, Csima A, Price V (1990) The effectsof asingle night's dosing with triazolam on sleep the following night. J Clin Pharmacol 30:549-555
16. Langley MS, Clissold SP (1988) Brotizolam; a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. Drugs 35:104-122
17. Mamelak M, Csima A, Buck L, Price V (1989) A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol 9:260-267
18. Kales A, Bixler EO, Soldatos CR (1986) Lorazepam: effects on sleep and withdrawal phenomena. Pharmacology 32:121-130
19. Oswald I, Adam K, Borrow S et al (1979) The effectsoftwo hypnotics on sleep, subjective feelings and skilled performance. In: O Pussouant, I Oswald (eds): Pharmacology of the states of alertness. Pergamon, Oxford, 51-63
20. Woods JH, Winger G (1997) Abuse liability of flunitrazepam. J Clin Psychopharmacol 17, 3 Suppl 2:1-57
21. Chouinard G (2004) Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 65, Suppl 5:7-12
22. Dorian P, Sellers EM, Kaplan H (1983) Evaluation of zopiclone physical dependence liability in normal volunteers. Pharmacology 27, Suppl 2:228-234
23. Lader M, Frcka G (1987) Subjective effects during administration ad on discontinuation of zopiclone and temazepam in normal subjects. Pharmacopsychiatry 20:67-71
24. Tiberge M, Calvet V, Khayi N et al. (1988) Comparison des effets de la zopiclone et du triazolam sur le sommeil du sujet sain. Encéphale 14:319-324
25. Fontaine R, Beaudry P, Le Morvan P et al. (1988) Efficacy and rebound insomnia of zopiclone and triazolam. Psychopharmacology 96, Suppl: 219
26. Fontaine R, Beaudry P, Le Morvan P, Beauclair L, Chouinard G (1990) Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol 5:173-183
27. Soldatos CR, Dikeos DG (1993) Efficacy and rebound of five hypnotics in the elderly: a critical review. In: L Vellas, JL Albarede (eds): Sleep disorders and insomnia in the elderly. Serdi, Paris, 209-221
28. Lader M (1997) Zopiclone: is there any dependence and abuse potential? J Neurol 244, Suppl 1:S18-S22
29. Chiffoleau A, Baudot S, Larousse C et al (1991) Zopiclone: what does happen after discontinuation of long-term treatment? Proceedings of 13eme Journees Francaises de Pharmacovigilance. Oct. 28-29, Nice
30. Lemoine P, Allain H, Janus C (1995) Gradual withdrawal of zopiclone (7.5mg) and zolpidem (10mg) in insomniacs treated for at least 3 months. Eur J Psychiatry 10 Suppl 316:1S-165S
31. Pat-Horenczyk R, Hacohen D, Herer P, Lavie P (1998) The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology 140:450-457
32. Lemoine P, Ohayon M (1997) Is hypnotic withdrawal facilitated by the transitory use of a substitute drug? Prog Neuropsychopharmacol Biol Psychiatry 21:111-124
33. Voderholzer U, Riemann D, Hornyak M, Backhaus J, Feige B, Berger M, Hohagen F (2001) A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Eur Arch Psychiat Clin Neurosci 251:117-123
34. Hajak G (1999) A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience. Drug Safety 21:457-469
35. Bianchi M, Musch B (1990) Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Psychopharmacol 5, Suppl 2:139-145
36. Holm KJ, Goa KL (2000) Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59:865-889
37. Freeman H, Puech AJ, Roth T (eds) (1996) Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Elsevier, Paris
38. Vogel G, Poirrier R (1996) Studies of effects following discontinuation of zolpidem treatment. In: H Freeman, AJPuech, T Roth (eds): Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Elsevier, Paris: 149-160
39. Monti JM, Monti D, Estevez F, Giusti M (1996) Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol 11:255-263
40. Biondi F, Casadei GL (1994) Results of a multicentre trial with the hypnotic zolpidem in 1152 insomniac patients. Curr Ther Res 55:262-274
41. Lorizio A, Terzano MG, Parino L etal (1990) Zolpidem: a double-blind comparison ofthe hypnotic activity and safety of a 10-mg versus 20-mg dose. Curr Ther Res 47:889-898
42. Schlich D, L'Heritier C, Coquelin JP, Attali P, Kryrein HJ (1991) Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 19:271-279
43. Allain H, Rahola JG (1996) Switching to zolpidem in patients habituated to long-term benzodiazepine use. In: H Freeman, AJ Puech, T Roth (eds): Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Elsevier, Paris, 176-182
44. Allain H, Le Coz F, Borderies P, Schuck S, de La Giclais B, Patat A, Gandon JM (1998) Use of zolpidem 10 mg as a benzodiazepine substitute in 84 patients with insomnia. Human Psychopharmacol Clin Exp 13:551-559
45. Allain H, Arbus L, Schück S, Zolpidem Study Group (2001) Efficacy and safety of zolpidem administered "as needed" in primary insomnia. Clin Drug Invest 21:391-400
46. Hajak G, Cluydts R, Declerck A, Estvill SE, Middleton A, Sonka K, Unden M (2002) Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a largescale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol 17:9-17
47. Swainston Harrison T, Keating GM (2005) Zolpidem: a review of its use in the management of insomnia. CNS Drugs 19:65-89
48. Fry J, Scharf M, Mangano R, Fujimori M (2000) Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Int Clin Psychopharmacol 15:141-152
49. Israel AG, Kramer JA (2002) Safety of zaleplon in the treatment of insomnia. Ann Pharmacother 36:852-859
50. Barbera J, Shapiro C (2005) Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Safety 28:301-318
51. Mukai M, Uchimura N, Takeuchi N, Kuwakara H, Hashizume Y, Nose I, Satomura T, Tanaka J, Maeda H (2001) Study on withdrawal of hypnotics: questionnaire on hypnotic use and its withdrawal. Psychiat Clin Neurosci 55:209-210
52. Dundar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, Bogg J, Dickson R, Walley T (2004) Newer hypnotic drugs for the short-management of insomnia: a systematic review and economic evaluation. Health Technolol Assess 8:1-125
53. Wagner J, Wagner ML (2000) Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 4:551-581
54. Drake CL, Roehrs T, Roth T (2003) Insomnia causes, consequences, and therapeutics: an overview. Depression and Anxiety 18:163-176
55. Lader M (2002) Sleep disorders - therapeutic armamentarium. In: H D'Haenen, JA Den Boer, P Willner (eds): Biological Psychiatry. John Wiley, Chichester, 1307-1314